Phase 2 N=23 Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Childhood Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Overall Survival (OS) — 86; 56 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine
Oncology Patients Receiving Chemotherapy
Primary: Number of Hypersensitivity Reactions to Treatment With an Anti-CD20 Antibody or Paclitaxel — 2; 3 Participants
Phase 2 N=29 Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Leukemia · Lymphoma · Small Intestine Cancer
Primary: Maximum Tolerated Dose — 20 mg/m2 of clofarabine
Phase 2 N=22 Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4
Chronic Kidney Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 6; 2 Participants
Phase 2 N=13 Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
Graft-versus-host Disease · Hematopoietic Stem Cell Transplantation
Primary: Safety of Maraviroc — 8; 6; 18 Number of AEs
Phase 2 N=41 Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
Chikungunya Virus Infection
Primary: Number of Participants With Solicited Adverse Events (AEs) — 15; 11 Participants
Phase 2 N=291 Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
Neuroblastoma
Primary: Efficacy at Completion of Treatment
Phase 2 N=61 Efavirenz in Treating Patients With Metastatic Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants Without Prostate-specific Antigen Progression at 3 Months — 28.3 percentage of participants
Phase 2 N=34 Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability
Alzheimer's Disease
Primary: Changes in Executive Function as Measured by the NIH EXAMINER Computer Battery — -0.06; -0.14 score on a scale — p=0.55
Phase 2 N=17 Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation
Renal Disease
Primary: Number of Participants With Allograft Rejection — 7 Participants
Phase 2 N=31 Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)
Meibomian Gland Dysfunction
Primary: Meibum Gland Secretion Score (MGS) — 0.5; 7.4 score on a scale
Phase 2 N=152 Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder
Post-Traumatic Stress Disorder
Primary: CAPS-5 [Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)] Total Score and Subscores — -13.4; -15.7…
Phase 2 N=51 Peanuts and Glycemic Control
Type2 Diabetes · Cardiovascular Diseases
Primary: Fasting Plasma Glucose — -0.9; -0.4 mg/dL
Phase 2 N=88 A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
Triple-negative Breast Cancer
Primary: Overall Response Rate (ORR) Per Investigator's Assessment According to RECIST v1.1 — 5.0; 32.4; 17.6 Percentage of participants
Phase 2 N=41 Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility
Recurrent Pregnancy Loss · Unexplained Infertility
Primary: Abnormal Microbiome Bacterial Sequencing